Correct Method for Adjusting Drug Prices
TL/DR –
The author argues that U.S. is shouldering the cost of global pharmaceutical research and development, as wealthy allied nations suppress what they pay for drugs. The author criticizes the approach to import prices that trading partners extract through market manipulation, and suggests using Section 301 of the Trade Act of 1974 against unfair foreign trade practices. The author urges the U.S. to use this tool to negotiate bilateral agreements requiring higher pharmaceutical spending targets and science-based benefit assessments, compelling nations to pay their fair share.
“`html
Trump Administration Aims to Tackle International Pharmaceutical Pricing Disparities
The Trump administration is attempting to redress the imbalances in global pharmaceutical pricing, with the hope of reducing the cost of drugs for American consumers. The administration is scrutinizing several wealthy nations with complex systems that keep their drug prices low, indirectly causing American patients and taxpayers to bear the brunt of global pharmaceutical research and development costs.
Countries like Germany, Japan, Canada, Italy, Spain, and South Korea are under the spotlight, as their pricing models disproportionately benefit their citizens at the expense of Americans. The Trump administration’s effort to address this issue deserves commendation.
Addressing the Trade Issue
Though the administration is making strides, it’s important to ensure the solution mirrors the problem. There are ongoing discussions in Washington about narrowing the price gap, and some are suggesting domestic price controls. However, adopting foreign governments’ pricing structures would not only reward these countries’ market manipulation but would also hamper the innovation they rely on.
A more effective approach might be to utilize Section 301, a powerful enforcement instrument against unfair foreign trade practices.
Unfair Practices of Allied Governments
In examining how countries like Germany handle American medicines, one can observe that they deliberately adopt strategies that result in lower drug prices. Mandatory rebates on patented medicines and a price freeze implemented in 2010 are all part of Germany’s plan to spend as little as possible on innovative drugs. This has resulted in Germany’s drug spending being only 0.36% of its GDP, compared to the United States’ 0.78%.
Germany’s practices essentially force American patients to subsidize the cost of pharmaceuticals for Germans. Other allied nations like Japan and Switzerland are also following suit, pushing the United States to bear the costs of global drug development. This systemic free-riding necessitates a trade response.
The Drawbacks of Price Controls
Simply capping domestic drug prices in line with what Germany or Japan pays is not a viable solution. This approach would inadvertently endorse an unjust global system and could potentially stifle the innovation that has allowed the U.S. pharmaceutical sector to lead the world in drug development.
Section 301 as a Potential Solution
Section 301 of the Trade Act of 1974 empowers the United States to take action against unfair foreign trade practices. Using it to address the issue of global pharmaceutical pricing could send a strong message to trading partners that the United States will no longer solely shoulder the costs of pharmaceutical innovation.
Earlier this year, a pricing arrangement between the United States and Britain demonstrated the effectiveness of this tool. This precedent-setting agreement, which required Britain to increase its spending on innovative medicines in return for significantly lower tariffs, proves the efficacy of credible American trade pressure.
In fact, the U.S. Trade Office has already initiated a Section 301 investigation into Germany’s pricing policies. The office should consider extending its investigations to other countries like Japan, Canada, Italy, Spain, and South Korea.
By using Section 301 investigations to negotiate bilateral agreements, the office could bring about an end to the unfair pricing regimes that have allowed allied healthcare systems to benefit from American innovation without bearing their fair share of the costs.
The Trump administration is rightfully prioritizing the issue of foreign pharmaceutical freeloading. To truly address this issue, it should consider targeting solutions like Section 301 that can enforce fair trade without punishing American innovators.
“`
—
Read More US Economic News